| 分子亚型 |
|
| 0.473 | 0.789 |
| 三阴性 | 14 | 4 |
|
|
| Lunminal型 | 9 | 3 |
|
|
| HER-2过表达型 | 5 | 2 |
|
|
| 优替德隆治疗线数 |
|
| 2.633 | 0.105 |
| ≤三线治疗 | 11 | 5 |
|
|
| ≥四线治疗 | 17 | 3 |
|
|
| Ki67%指数 |
|
| 7.674 | 0.006 |
| ≤30 (低表达) | 7 | 2 |
|
|
| >30 (高表达) | 21 | 5 |
|
|
| 疗效评价 |
|
| 16.568 | <0.001 |
| PR | 6 | 5 |
|
|
| SD | 16 | 3 |
|
|
| PD | 6 | 2 |
|
|